Hypothesis: Hyperhomocysteinemia is an indicator of oxidant stress

Medical Hypotheses

Volumn 77, Issue 6, 2011, Pages 1088-1093

  Hoffman, Maureane ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FOLIC ACID; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE;

AMINO ACID METABOLISM; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL DAMAGE; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERHOMOCYSTEINEMIA; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; THROMBOCYTE ACTIVATION; VITAMIN SUPPLEMENTATION;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM; FOLIC ACID; HYPERHOMOCYSTEINEMIA; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; OXIDATIVE STRESS;

EID: 80755140110     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.09.009     Document Type: Article

References (43)

1. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
2. Eichinger S., Stumpflen A., Hirschl M., et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998, 80:566-569.
3. Hankey G.J., Eikelboom J.W. Homocysteine and vascular disease. Lancet 1999, 354:407-413.
4. Lentz S.R. Mechanisms of thrombosis in hyperhomocysteinemia. Curr Opin Hematol 1998, 5:343-349.
5. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
6. Sato Y., Honda Y., Iwamoto J., Kanoko T., Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005, 293:1082-1088.
7. Elias M.F., Sullivan L.M., D'Agostino R.B., et al. Homocysteine and cognitive performance in the Framingham offspring study: age is important. Am J Epidemiol 2005, 162:644-653.
8. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002, 346:476-483.
9. Cho N.H., Lim S., Jang H.C., Park H.K., Metzger B.E. Elevated homocysteine as a risk factor for the development of diabetes in women with a previous history of gestational diabetes mellitus: a 4-year prospective study. Diabetes Care 2005, 28:2750-2755.
10. Looker H.C., Fagot-Campagna A., Gunter E.W., et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 2003, 46:766-772.
11. Finkelstein J.D. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998, 157(Suppl. 2):S40-S44.
12. Ubbink J.B., Vermaak W.J., van der Merwe A., Becker P.J. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993, 57:47-53.
13. Bostom A.G., Shemin D., Lapane K.L., et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996, 123:193-202.
14. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042-1050.
15. Starkebaum G., Harlan J.M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986, 77:1370-1376.
16. Blundell G., Jones B.G., Rose F.A., Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996, 122:163-172.
17. Huang R.F., Hsu Y.C., Lin H.L., Yang F.L. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr 2001, 131:33-38.
18. Chern C.L., Huang R.F., Chen Y.H., Cheng J.T., Liu T.Z. Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. Biomed Pharmacother 2001, 55:434-442.
19. Tyagi N., Ovechkin A.V., Lominadze D., Moshal K.S., Tyagi S.C. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem 2006, 98(5):1150-1162.
20. Zeng X., Dai J., Remick D.G., Wang X. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res 2003, 93:311-320.
21. Signorello M.G., Pascale R., Leoncini G. Reactive oxygen species accumulation induced by homocysteine in human platelets. Ann NY Acad Sci 2002, 973:546-549.
22. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996, 98:5-7.
23. Olszewski A.J., McCully K.S. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993, 14:683-693.
24. Welch GN, Upchurch Jr GR, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract (Off Ed) 1997;32:81-2, 5, 8-92.
25. Dayal S., Lentz S.R. Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals. Antioxid Redox Signal 2007, 9:1899-1909.
26. Mark S.D., Wang W., Fraumeni J.F., et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol 1996, 143:658-664.
27. Lonn E. Homocysteine-lowering B vitamin therapy in cardiovascular prevention - wrong again?. JAMA 2008, 299:2086-2087.
28. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-575.
29. Song Y., Cook N.R., Albert C.M., Van Denburgh M., Manson J.E. Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009, 58:1921-1928.
30. Zoungas S., McGrath B.P., Branley P., et al. Cardiovascular morbidity and mortality in the atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006, 47:1108-1116.
31. Wrone E.M., Hornberger J.M., Zehnder J.L., McCann L.M., Coplon N.S., Fortmann S.P. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004, 15:420-426.
32. Oakley G.P., Adams M.J., Dickinson C.M. More folic acid for everyone, now. J Nutr 1996, 126:751S-755S.
33. Bostom A.G., Selhub J., Jacques P.F., Rosenberg I.H. Power shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med 2001, 135:133-137.
34. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans 2003, 31:1059-1061.
35. Chippel D., Scrimgeour K.G. Oxidative degradation of dihydrofolate and tetrahydrofolate. Can J Biochem 1970, 48:999-1009.
36. Maruyama T., Shiota T., Krumdieck C.L. The oxidative cleavage of folates. A critical study. Anal Biochem 1978, 84:277-295.
37. Joshi R., Adhikari S., Patro B.S., Chattopadhyay S., Mukherjee T. Free radical scavenging behavior of folic acid: evidence for possible antioxidant activity. Free Radic Biol Med 2001, 30:1390-1399.
38. Fuchs D., Jaeger M., Widner B., Wirleitner B., Artner-Dworzak E., Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake?. Clin Chem Lab Med 2001, 39:691-694.
39. Racek J., Rusnakova H., Trefil L., Siala K.K. The influence of folate and antioxidants on homocysteine levels and oxidative stress in patients with hyperlipidemia and hyperhomocysteinemia. Physiol Res 2005, 54:87-95.
40. Ploder M., Kurz K., Spittler A., Neurauter G., Roth E., Fuchs D. Early increase of plasma homocysteine in sepsis patients with poor outcome. Mol Med 2010, 16:498-504.
41. Schroecksnadel K., Frick B., Winkler C., Leblhuber F., Wirleitner B., Fuchs D. Hyperhomocysteinemia and immune activation. Clin Chem Lab Med 2003, 41:1438-1443.
42. Sauls D.L., Arnold E.K., Bell C.W., Allen J.C., Hoffman M. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Thromb Res 2007, 120:117-126.
43. Sauls D.L., Wolberg A.S., Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 2003, 1:300-306.